Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Jan 22;138(1):262–273.e6. doi: 10.1016/j.jaci.2015.11.018

FIG 2.

FIG 2

A–C, Transfer of ALNCs from donors immunized with OVA alone, OVA plus CpG, or TNP-Ig plus CpG into recipients subsequently immunized and challenge with OVA (Fig 2, A) and their effects on production of OVA-specific IgE (Fig 2, B) and IgG2a (Fig 2, C). D–F, Transfer of ALNCs from donors immunized with OVA alone or OVA and CpG into recipients subsequently challenged with OVA (Fig 2, D) and secretion of OVA-specific IgE (Fig 2, E) and IgG2a (Fig 2, F). Fig 2, B and C, n = 4–5; Fig 2, D and E, n = 6–8. ns, Not significant. *P < .05 and ***P < .001. EC, Epicutaneous.